BioMarin Pharma (BMRN) Tops Q1 EPS by 20c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $63.94 -1.75%
Revenue Growth %: +31.4%
Financial Fact:
Intangible asset amortization and contingent consideration: 9.65M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +31.4%
Financial Fact:
Intangible asset amortization and contingent consideration: 9.65M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q1 GAAP EPS of ($0.09), $0.20 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $304 million versus the consensus estimate of $288.98 million.
Non-GAAP income for the first quarter ended March 31, 2017 was $35 million, compared to non-GAAP loss of $29 million for the quarter ended March 31, 2016.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $97 at BMO Capital
- JPMorgan Reiterates Overweight Rating on Samsung Electronics Co Ltd. (005930:KS) (SSNLF)
- Faraday Future unveils nine robot models, prices start at $9,990
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
